Evidence map›Paper›PMID 31204599›Full record

ArticleTechnology in cancer research & treatment2019

A Pretreatment CT Model Predicts Survival Following Chemolipiodolization in Patients With Hepatocellular Carcinoma.

Yijun Zhang, Shuping Qu, Wanwan Yi, Jian Zhai, Xiaobing Zhang, Lixin Wei, Wan Yee Lau, Mengchao Wu, Feng Shen, Hengwei Fan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yijun Zhang1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Shuping Qu1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Wanwan Yi3 Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Jian Zhai2 Department of Radiological Intervention treatment, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Xiaobing Zhang2 Department of Radiological Intervention treatment, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Lixin Wei4 Tumor Immunology and Gene Therapy Center, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Wan Yee Lau1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Mengchao Wu1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Feng Shen1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Hengwei Fan1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Dong Wu1 Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo establish a computed tomography-based prognostic model for patients with hepatocellular carcinoma treated with transarterial chemoembolization. MATERIALS AND

methodsUsing prospectively collected data from 195 consecutive patients with hepatocellular carcinoma who underwent chemolipiodolization at the Eastern Hepatobiliary Surgery Hospital between 2013 and 2016, we established a prognostic model based on hepatocellular carcinoma enhancement patterns on computed tomography scans to predict the outcome of transarterial chemoembolization. Furthermore, a histopathology analysis was performed on 108 different patients undergoing resection between 2014 and 2016 to identify whether there was a correlation between enhancement pattern and microvessel density.

resultsThe prognostic model classified hepatocellular carcinoma into 3 types: type I, which reached peak enhancement during the arterial phase and had a high mean microvessel density (101.5 vessels/0.74 mm

conclusionOur results indicate that hepatocellular carcinoma type is an independent predictor of complete necrosis and overall survival.

Indexed as

Tomography, X-Ray ComputedAdultAgedCarcinoma, HepatocellularChemoembolization, TherapeuticDisease ManagementFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingNeovascularization, PathologicPrognosisTreatment Outcomecomputed tomographyhepatocellular carcinomaprognosistransarterial chemoembolizationtumor vascularity

Identifiers

PMID31204599
PMCPMC6582374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.